Kiran K Khush1. 1. Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Abstract
PURPOSE OF REVIEW: We are entering the era of personalized medicine, in which pharmacogenomics and biomarker-based assays can be used to tailor diagnostic tests and drug therapies to individual patients. This new approach to patient-specific care offers the potential to maximize the efficacy of available medical treatments while reducing the incidence of adverse side effects. Here, we present approaches to personalize the care of heart transplant recipients. RECENT FINDINGS: Four strategies for personalized posttransplant care are described, including use of pharmacogenomic data to individualize the use of immunosuppressive drugs, immune monitoring to prevent acute rejection while reducing the long-term consequences of over immunosuppression, noninvasive surveillance for acute rejection, and targeted prophylaxis against opportunistic infections. SUMMARY: The long-term survival of heart transplant recipients is limited by side effects of immunosuppressive drugs, including infectious complications, renal dysfunction, and malignancy. We discuss strategies to maximize the benefits of immunosuppressive and prophylactic therapies while minimizing their long-term toxicities.
PURPOSE OF REVIEW: We are entering the era of personalized medicine, in which pharmacogenomics and biomarker-based assays can be used to tailor diagnostic tests and drug therapies to individual patients. This new approach to patient-specific care offers the potential to maximize the efficacy of available medical treatments while reducing the incidence of adverse side effects. Here, we present approaches to personalize the care of heart transplant recipients. RECENT FINDINGS: Four strategies for personalized posttransplant care are described, including use of pharmacogenomic data to individualize the use of immunosuppressive drugs, immune monitoring to prevent acute rejection while reducing the long-term consequences of over immunosuppression, noninvasive surveillance for acute rejection, and targeted prophylaxis against opportunistic infections. SUMMARY: The long-term survival of heart transplant recipients is limited by side effects of immunosuppressive drugs, including infectious complications, renal dysfunction, and malignancy. We discuss strategies to maximize the benefits of immunosuppressive and prophylactic therapies while minimizing their long-term toxicities.
Authors: M Grimm; M Rinaldi; N A Yonan; G Arpesella; J M Arizón Del Prado; L A Pulpón; J P Villemot; M Frigerio; J L Rodriguez Lambert; M G Crespo-Leiro; L Almenar; D Duveau; A Ordonez-Fernandez; J Gandjbakhch; M Maccherini; G Laufer Journal: Am J Transplant Date: 2006-06 Impact factor: 8.086
Authors: J A Kobashigawa; L W Miller; S D Russell; G A Ewald; M J Zucker; L R Goldberg; H J Eisen; K Salm; D Tolzman; J Gao; W Fitzsimmons; R First Journal: Am J Transplant Date: 2006-06 Impact factor: 8.086
Authors: Omar Wever-Pinzon; Leah B Edwards; David O Taylor; Abdallah G Kfoury; Stavros G Drakos; Craig H Selzman; James C Fang; Lars H Lund; Josef Stehlik Journal: J Heart Lung Transplant Date: 2016-08-20 Impact factor: 10.247
Authors: Diana M Girnita; Steven A Webber; Robert Ferrell; Gilbert J Burckart; Maria M Brooks; Kevin K McDade; Richard Chinnock; Charles Canter; Linda Addonizio; Daniel Bernstein; James K Kirklin; Alin L Girnita; Adriana Zeevi Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: Richard Kowalski; Diane Post; Mary C Schneider; Judith Britz; Judy Thomas; Mark Deierhoi; Andrew Lobashevsky; Robert Redfield; Eugene Schweitzer; Alonso Heredia; Elise Reardon; Charles Davis; Carol Bentlejewski; John Fung; Ron Shapiro; Adriana Zeevi Journal: Clin Transplant Date: 2003-04 Impact factor: 2.863
Authors: Mats Hidestrand; Aoy Tomita-Mitchell; Pip M Hidestrand; Arnold Oliphant; Mary Goetsch; Karl Stamm; Huan-Ling Liang; Chesney Castleberry; D Woodrow Benson; Gail Stendahl; Pippa M Simpson; Stuart Berger; James S Tweddell; Steven Zangwill; Michael E Mitchell Journal: J Am Coll Cardiol Date: 2013-10-16 Impact factor: 24.094
Authors: Christopher Vollmers; Iwijn De Vlaminck; Hannah A Valantine; Lolita Penland; Helen Luikart; Calvin Strehl; Garrett Cohen; Kiran K Khush; Stephen R Quake Journal: PLoS Med Date: 2015-10-14 Impact factor: 11.069
Authors: Hajnalka Andrikovics; Zoltán Őrfi; Nóra Meggyesi; András Bors; Lívia Varga; Petra Kövy; Zsófia Vilimszky; Fanni Kolics; László Gopcsa; Péter Reményi; Attila Tordai Journal: Int J Mol Sci Date: 2019-09-10 Impact factor: 5.923